Skip to Content

Evolution of MS Treatments

Henrik Ahvenjarvi, MD, PhD student from the University of Oulu, conducted a retrospective study, along with his team, on the evolution of initial disease-modifying treatments for relapse remitting multiple sclerosis in Finland from 2013 to 2022. Among others, the study showed an increase in high efficacy treatments from 7% to 44%, with a decrease in medium efficacy treatments. Watch the MEDtalk and find out more.

Henrik Ahvenjarvi

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top